What is Leerink Partnrs’ Estimate for EW FY2024 Earnings?

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Leerink Partnrs increased their FY2024 earnings estimates for shares of Edwards Lifesciences in a research note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings per share of $2.58 for the year, up from their previous forecast of $2.57. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q1 2025 earnings at $0.57 EPS, Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.62 EPS, Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.46 EPS and FY2027 earnings at $3.33 EPS.

A number of other analysts also recently issued reports on EW. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Wells Fargo & Company lowered their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Jefferies Financial Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, Piper Sandler lowered their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $75.90.

Edwards Lifesciences Stock Up 0.7 %

EW opened at $72.06 on Wednesday. The company has a fifty day moving average price of $67.92 and a 200-day moving average price of $75.35. The firm has a market capitalization of $42.50 billion, a P/E ratio of 10.40, a price-to-earnings-growth ratio of 4.01 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the business earned $0.59 EPS. Edwards Lifesciences’s revenue was up 8.9% compared to the same quarter last year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,000 shares of company stock valued at $2,657,000. 1.27% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its holdings in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after buying an additional 14,610,123 shares during the period. State Street Corp grew its stake in Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after purchasing an additional 256,538 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after acquiring an additional 809,605 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after acquiring an additional 284,918 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Edwards Lifesciences by 9.8% during the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after acquiring an additional 806,705 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.